Keywords: Shire, Replagal, VPRIV, Firazyr, Gaucher, Fabry, HAE
Shire presents new data for Replagal and VPRIV; gets PUDFA date for Firazyr
Article | 22 March 2011
Ireland-headquartered biopharma company Shire (LSE: SHP) presented new data for Replagal (agalsidase alfa) in patients with Fabry disease, and VPRIV ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
